The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Meiji Launches Japan PIII of mRNA COVID Shot for BA.4/5 Strain
Meiji Seika Pharma said on September 29 that it has initiated a PIII booster trial in Japan to investigate ARCT-2301, a bivalent self-amplifying mRNA COVID-19 vaccine based on the ancestral strain and Omicron BA.4/5 subvariants of the novel coronavirus. The…
To read the full story
Related Article
- Meiji Seeks Booster Nod for COVID-19 mRNA Vaccine in Japan
July 3, 2023
- Meiji Files CSL Seqirus’ mRNA COVID Vaccine in Japan
May 1, 2023
- Meiji/CSL Seqirus Tie Up for Sales of COVID-19 mRNA Vaccine in Japan
April 12, 2023
- Mejii Kicks Off Japan PIII for Arcturus’ COVID mRNA Vaccine
December 14, 2022
- Meiji Pharma Eyes Japan Filing of Arcturus’ COVID Vaccine Next Spring
November 2, 2022
- Meiji Pharma in Talks on Japan Rights to Arcturus’ COVID Jab Candidate
August 26, 2022
BUSINESS
- Sanofi Files Dupixent for CSU in Children Aged 2-11 in Japan
December 26, 2025
- Enhertu Wins 5th China Indication in HER2-Low/Ultralow Breast Cancer
December 26, 2025
- SymBio Bags Rights to Develop Antiviral Brincidofovir for Alzheimer’s
December 26, 2025
- Dayvigo Wins Triple Crown in November HP Promotion List: Intage
December 26, 2025
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…